Sigyn Therapeutics Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
SIGY Over the counter 3841 https://www.sigyntherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sigyn Therapeutics Inc

Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application - May 17th, 2023 11:00 am
Sigyn Therapeutics Reports First Quarter 2023 Financial Results - May 16th, 2023 11:30 am
Sigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer - Apr 11th, 2023 12:30 pm
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K - Mar 31st, 2023 1:45 pm
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results - Nov 15th, 2022 12:30 pm
Sigyn Therapeutics™ Discloses Trademark Applications to Register ChemoPrep™ and ChemoPure™ for Devices to Enhance Cancer Therapy - Oct 13th, 2022 12:30 pm
Sigyn Therapeutics™ Announces Cancer-Related Patent Submission Entitled: “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity” - Oct 6th, 2022 12:30 pm
Sigyn Therapeutics™ Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel - Oct 4th, 2022 1:00 pm
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients - Sep 14th, 2022 1:00 pm
Sigyn Therapeutics Announces Second Quarter 2022 Financial Results - Aug 15th, 2022 1:40 pm
Sigyn Therapeutics to Commence Trading on the OTCQB® Venture Exchange - Aug 3rd, 2022 10:30 am